Pharmacogenomics of endocrine therapy in breast cancer

James N. Ingle

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The most important modality of treatment in the two-thirds of patients with an estrogen receptor (ER)-positive early breast cancer is endocrine therapy. In postmenopausal women, options include the selective ER modulators (SERMs), tamoxifen and raloxifene, and the 'third-generation' aromatase inhibitors (AIs), anastrozole, exemestane and letrozole. Under the auspices of the National Institutes of Health Global Alliance for Pharmacogenomics, Japan, the Mayo Clinic Pharmacogenomics Research Network Center and the RIKEN Center for Genomic Medicine have worked collaboratively to perform genome-wide association studies (GWAS) in women treated with both SERMs and AIs. On the basis of the results of the GWAS, scientists at the Mayo Clinic have proceeded with functional genomic laboratory studies. As will be seen in this review, this has led to new knowledge relating to endocrine biology that has provided a clear focus for further research to move toward truly personalized medicine for women with breast cancer.

Original languageEnglish (US)
Pages (from-to)306-312
Number of pages7
JournalJournal of Human Genetics
Volume58
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Pharmacogenetics
Aromatase Inhibitors
exemestane
letrozole
Genome-Wide Association Study
Breast Neoplasms
Insurance Pools
Selective Estrogen Receptor Modulators
Precision Medicine
National Institutes of Health (U.S.)
Tamoxifen
Research
Estrogen Receptors
Japan
Therapeutics
Medicine

Keywords

  • aromatase inhibitors
  • breast cancer
  • pharmacogenomics
  • tamoxifen

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Pharmacogenomics of endocrine therapy in breast cancer. / Ingle, James N.

In: Journal of Human Genetics, Vol. 58, No. 6, 06.2013, p. 306-312.

Research output: Contribution to journalArticle

Ingle, James N. / Pharmacogenomics of endocrine therapy in breast cancer. In: Journal of Human Genetics. 2013 ; Vol. 58, No. 6. pp. 306-312.
@article{4d0be9c2d9fb40508f0effee32284aa0,
title = "Pharmacogenomics of endocrine therapy in breast cancer",
abstract = "The most important modality of treatment in the two-thirds of patients with an estrogen receptor (ER)-positive early breast cancer is endocrine therapy. In postmenopausal women, options include the selective ER modulators (SERMs), tamoxifen and raloxifene, and the 'third-generation' aromatase inhibitors (AIs), anastrozole, exemestane and letrozole. Under the auspices of the National Institutes of Health Global Alliance for Pharmacogenomics, Japan, the Mayo Clinic Pharmacogenomics Research Network Center and the RIKEN Center for Genomic Medicine have worked collaboratively to perform genome-wide association studies (GWAS) in women treated with both SERMs and AIs. On the basis of the results of the GWAS, scientists at the Mayo Clinic have proceeded with functional genomic laboratory studies. As will be seen in this review, this has led to new knowledge relating to endocrine biology that has provided a clear focus for further research to move toward truly personalized medicine for women with breast cancer.",
keywords = "aromatase inhibitors, breast cancer, pharmacogenomics, tamoxifen",
author = "Ingle, {James N.}",
year = "2013",
month = "6",
doi = "10.1038/jhg.2013.35",
language = "English (US)",
volume = "58",
pages = "306--312",
journal = "Journal of Human Genetics",
issn = "1434-5161",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Pharmacogenomics of endocrine therapy in breast cancer

AU - Ingle, James N.

PY - 2013/6

Y1 - 2013/6

N2 - The most important modality of treatment in the two-thirds of patients with an estrogen receptor (ER)-positive early breast cancer is endocrine therapy. In postmenopausal women, options include the selective ER modulators (SERMs), tamoxifen and raloxifene, and the 'third-generation' aromatase inhibitors (AIs), anastrozole, exemestane and letrozole. Under the auspices of the National Institutes of Health Global Alliance for Pharmacogenomics, Japan, the Mayo Clinic Pharmacogenomics Research Network Center and the RIKEN Center for Genomic Medicine have worked collaboratively to perform genome-wide association studies (GWAS) in women treated with both SERMs and AIs. On the basis of the results of the GWAS, scientists at the Mayo Clinic have proceeded with functional genomic laboratory studies. As will be seen in this review, this has led to new knowledge relating to endocrine biology that has provided a clear focus for further research to move toward truly personalized medicine for women with breast cancer.

AB - The most important modality of treatment in the two-thirds of patients with an estrogen receptor (ER)-positive early breast cancer is endocrine therapy. In postmenopausal women, options include the selective ER modulators (SERMs), tamoxifen and raloxifene, and the 'third-generation' aromatase inhibitors (AIs), anastrozole, exemestane and letrozole. Under the auspices of the National Institutes of Health Global Alliance for Pharmacogenomics, Japan, the Mayo Clinic Pharmacogenomics Research Network Center and the RIKEN Center for Genomic Medicine have worked collaboratively to perform genome-wide association studies (GWAS) in women treated with both SERMs and AIs. On the basis of the results of the GWAS, scientists at the Mayo Clinic have proceeded with functional genomic laboratory studies. As will be seen in this review, this has led to new knowledge relating to endocrine biology that has provided a clear focus for further research to move toward truly personalized medicine for women with breast cancer.

KW - aromatase inhibitors

KW - breast cancer

KW - pharmacogenomics

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84880866178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880866178&partnerID=8YFLogxK

U2 - 10.1038/jhg.2013.35

DO - 10.1038/jhg.2013.35

M3 - Article

VL - 58

SP - 306

EP - 312

JO - Journal of Human Genetics

JF - Journal of Human Genetics

SN - 1434-5161

IS - 6

ER -